Form 4: Enliven Therapeutics CEO Samuel Kintz Reports Stock Option Grant
SEC Form 4 Filing
Enliven Therapeutics' CEO, Samuel Kintz, reports the acquisition of stock options for 490,000 shares on February 6, 2025.
Summary
- Samuel Kintz, the President and CEO of Enliven Therapeutics, reported a transaction on February 6, 2025.
- He acquired stock options for 490,000 shares of Enliven Therapeutics common stock at an exercise price of $22.47 per share.
- The options vest over time, with 1/4th vesting on February 6, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continued service.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice that aligns management with shareholder interests. The vesting schedule indicates a long-term commitment.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Risks
- The vesting schedule is contingent upon the CEO's continued service, creating a potential risk if he were to leave the company before the options fully vest.
Future Outlook
The vesting schedule of the options suggests a long-term commitment from the CEO to the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The size of the grant (490,000 shares) would need to be compared to grants made to CEOs of similarly sized biotech companies to determine if it is above or below industry averages.
- Companies like Amgen, Gilead, and Regeneron often use stock options as part of their executive compensation, but the specific terms and amounts vary widely based on company performance and individual contributions.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/06/2025 | Date of the stock option grant. |
| 02/06/2026 | Date when 1/4th of the shares subject to the option will vest. |
| 02/10/2025 | Date of the signature on the Form 4 filing. |
| 02/06/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.